11 results about "Multigene expression" patented technology

The invention discloses a polygene expression cassette and a method for expressing I-type collagen in soybeans, and the method realizes rapid and efficient production of recombinant I-type collagen through a soybean seed expression system containing an optimized polygene expression cassette to express I-type collagen massively and stably. Moreover, the soybeans are the first oil crop in the world, the seeds of the soybeans are natural and free of toxic secondary metabolites, protein extraction does not need a complex detoxification process, in addition, the soybean seeds are stable in normal-temperature storage, the problem of rapid degradation of a leaf expression system (such as tobacco) is avoided, and the shelf life of the raw materials is remarkably prolonged.

This invention discloses the application of a biomarker in assessing the risk of prostate cancer recurrence, belonging to the field of tumor molecular diagnostics and bioinformatics technology. The biomarker includes at least one of the TACR2 and LPIN3 genes, and RCCD1, PRSS27, and NAP1L5, with the core detection focusing on the methylation-transcriptional combined characteristics of the TACR2 gene. This invention obtains patient samples, uses RT-qPCR to detect the expression levels of multiple genes, and methylation-specific PCR to detect the methylation level of the TACR2 promoter region. A risk scoring model is constructed using LASSO regression, and patient prognosis is stratified based on the score. This invention solves the problems of traditional assessment indicators being affected by tumor heterogeneity and having limited predictive accuracy. It is the first to use TACR2-related multi-omics characteristics for prostate cancer recurrence assessment. The multi-gene combined model improves predictive accuracy and can be developed into a standardized testing kit, providing a scientific basis for clinical recurrence risk assessment and personalized treatment, with significant industrial and clinical application value.

The invention discloses an engineering strain for improving the yield of cordycepin of cordyceps militaris based on polygene combination expression and precursor engineering and a construction method of the engineering strain, a strong promoter gpdA is adopted for driving, a P2A peptide connection strategy is utilized, and two polygene expression modules are constructed: firstly, cordycepin biosynthesis key genes cns1 and cns2 are overexpressed at the same time, and then the cordycepin biosynthesis key genes cns1 and cns2 are overexpressed at the same time; the terminal catalytic efficiency of the synthetic route is enhanced; and 2, the cns1 and a precursor supply gene nt5e are subjected to combined expression, so that the synergistic enhancement of precursor supply and terminal catalysis is realized. And introducing the expression module into cordyceps militaris through an agrobacterium-mediated method to obtain an engineering strain with genetic stability. A fermentation experiment shows that the cordycepin yield of the cns1-P2A-cns2 engineering strain reaches 186.5 mg / L, which is 2.3 times that of a wild type; and the yield of the cns1-P2A-nt5e engineering strain is further increased to 252.6 mg / L, which is 3.1 times that of a wild type. According to the invention, the induction cost is avoided, the construction is simple, the stability is strong, and a new strategy is provided for industrial efficient production of cordycepin.

According to the invention, a stable multi-gene expression system is constructed in chlamydomonas chloroplast for the first time, the expression system comprises a plurality of promoters and terminators, five gene expression units are successfully integrated at a single site of a chlamydomonas chloroplast genome, and meanwhile, one gene expression unit is integrated in a chlamydomonas nuclear genome. The establishment of the system promotes the development of chloroplast synthetic biology and metabolic engineering, and provides key technical support for synthesizing high-value compounds. On the basis of the gene expression system, a chlamydomonas engineering strain for expressing carboxylase is also constructed, a key foundation is laid for converting carboxylase into C3 crop chloroplast to improve the photosynthesis efficiency, meanwhile, technical support is provided for constructing a functional CO2 concentration mechanism in higher plants, and the final target is to improve the photosynthesis efficiency. Therefore, the crop yield is improved.

The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the present invention provides transgenic porcine animals, as well as organs, tissues and cells derived from the transgenic porcine animals, which lack any expression of a functional alpha 1,3 galactosyltransferase (GTKO) gene and comprise at least six transgenes under the control of at least three promoters within a single multi-gene expression vector, and further comprise at least four additional genetic modifications. Also provided are methods of making the transgenic animals (e.g., transgenic porcine animals), and methods of using the transgenic animals, organs, tissues, and cells derived from the transgenic animals for xenotransplantation therapies and treating a disease or condition.

This application relates to the field of molecular subtyping technology, specifically disclosing a molecular subtyping method for NK / T-cell lymphoma based on multi-gene expression characteristics and its application. The molecular subtyping method provided in this application can systematically reflect the molecular heterogeneity of NK / T-cell lymphoma, offers a standardized and reproducible molecular subtyping detection protocol, and can also assist in assessing patient prognostic risks and provide a reference for treatment decisions. The molecular subtyping method provided in this application is applicable to various conventional molecular detection platforms and has good clinical application value.

The invention relates to a method of predicting an outcome of a breast cancer subject, comprising determining or receiving the result of a determination of a gene expression profile comprising the expression levels of four or more genes selected from a first, a second and / or a third gene expression profile, wherein the first gene expression profile comprising one or more immune defense response genes selected from the group consisting of: AIM2, APOBEC3A, CIAO1, DDX58, DHX9, IFI16, IFIH1, IFIT1, IFIT3, LRRFIP1, MYD88, OAS1, TLR8, and ZBP1, and / or the second gene expression profile comprising one or more T-Cell receptor signalling genes selected from the group consisting of: CD2, CD247, CD28, CD3E, CD3G, CD4, CSK, EZR, FYN, LAT, LCK, PAG1, PDE4D, PRKACA, PRKACB, PTPRC, and ZAP70, and / or the third gene expression profile comprising one or more PDE4D7 correlated genes selected from the group consisting of: ABCC5, CUX2, KIAA1549, PDE4D, RAP1GAP2, SLC39A11, TDRD1, and VWA2, said gene expression profile being determined in a biological sample obtained from the subject, determining the prediction of the outcome based on the gene expression profile comprising the expression levels of the four or more genes, wherein said prediction is a favourable risk or a non-favourable risk of breast-cancer related death, loco-regional recurrence and / or distant recurrence.

The application discloses a tumor and paired cell line whole transcriptome RNA standard substance and a preparation method and application, wherein the tumor and paired cell line is a lung cancer and paired paracancer tissue immortalized cell line, is preserved in the China General Microbiological Culture Collection Center, and the preservation date is October 11, 2025; the lung cancer cell line biological preservation number is CGMCC No. 46703; and the paired paracancer tissue cell line biological preservation number is CGMCC No. 46704. The RNA standard substance includes two samples, is whole transcriptome RNA extracts of the tumor and paracancer tissue immortalized cell line of the same individual source in the Chinese genetic background, and the quantity value is the copy number concentration and the ratio of high confidence genes in the two samples. The whole transcriptome RNA standard substance can be used for performance evaluation of absolute quantification or relative quantification of multi-gene expression of detection data of different transcriptome sequencing technologies and sequencing platforms.

The present invention provides transgenic animals (e.g., transgenic porcine animals), organs, tissues, and cells derived from the transgenic animals that are particularly useful for xenotransplantation therapies. In particular, the present invention provides transgenic porcine animals, as well as organs, tissues and cells derived from the transgenic porcine animals, which lack any expression of a functional alpha 1,3 galactosyltransferase (GTKO) gene and comprise at least six transgenes under the control of at least three promoters within a single multi-gene expression vector, and further comprise at least four additional genetic modifications. Also provided are methods of making the transgenic animals (e.g., transgenic porcine animals), and methods of using the transgenic animals, organs, tissues, and cells derived from the transgenic animals for xenotransplantation therapies and treating a disease or condition.

The invention discloses a tumor and paired cell line whole transcriptome RNA standard substance and a preparation method and application thereof.The tumor and paired cell line is a lung cancer and paired para-carcinoma tissue immortalized cell line and is preserved in the China General Microbiological Culture Collection Center (CGMCC) on October 11, 2025, and the preservation number is CGMCC NO. The biological preservation number of the lung cancer cell line is CGMCC (China General Microbiological Culture Collection Center) No.46703, and the biological preservation number of the para-carcinoma tissue cell line is CGMCC No.46704. The RNA standard substance comprises two samples which are whole transcriptome RNA extracts of tumor and para-carcinoma tissue immortalized cell lines with the genetic background of Chinese and from the same individual, and the quantity value is the copy number concentration and the ratio of high-confidence genes in the two samples. The whole transcriptome RNA standard substance can be used for performance evaluation of absolute quantification or relative quantification of multi-gene expression of different transcriptome sequencing technologies and sequencing platform detection data.

The invention discloses an application of a COTL1high NK cell as a biomarker in prognosis of liver cancer. Based on in-depth study on tumor microenvironment, the invention finds that COTL1high NK cells are highly enriched in liver cancer which responds to immune checkpoint blocking (ICB) treatment and are related to good prognosis. According to the method, characteristic genes of COTL1high NK are analyzed, dynamic and polygene expression information is obtained, a marker capable of predicting liver cancer prognosis is found, a liver cancer prognosis model is established according to the marker and is used for predicting prognosis of a liver cancer patient, dynamic and polygene tumor microenvironment information can be obtained through the prediction method, and the prognosis of the liver cancer patient can be predicted according to the dynamic and polygene tumor microenvironment information. The prognosis of the liver cancer patient is accurately predicted.